Novo Nordisk A/S
(NYSE : NVO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 6.15%54.020.9%$2353.35m
JNJJohnson & Johnson -0.62%159.250.7%$1167.23m
MRKMerck & Co., Inc. -3.83%79.130.7%$1134.44m
LLYEli Lilly & Co. -0.57%260.501.1%$694.38m
BMYBristol-Myers Squibb Co. -0.53%56.511.0%$694.21m
ABBVAbbVie, Inc. -1.80%116.531.9%$669.66m
AZNAstraZeneca Plc 0.43%56.581.0%$278.35m
GSKGlaxoSmithKline Plc -1.42%41.010.2%$185.81m
NVSNovartis AG -1.44%80.730.2%$180.89m
BFRIBiofrontera, Inc. 51.34%7.900.0%$139.46m
VTRSViatris, Inc. -2.30%12.750.0%$132.99m
RGENRepligen Corp. 5.21%286.016.7%$112.80m
RPRXRoyalty Pharma Plc -0.45%41.890.1%$106.76m
DRNADicerna Pharmaceuticals, Inc. -0.03%37.990.3%$106.72m
NVONovo Nordisk A/S -0.76%108.210.1%$96.98m

Company Profile

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.